Note 8 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Lease, Cost [Table Text Block]

Operating leases	December 31, 2019
Operating ROU lease assets, noncurrent	$	13,493
Operating lease liabilities, current		599
Operating lease liabilities, noncurrent		15,005

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Years ending December 31,	Minimum Annual Payments
2020	$	2,040
2021		2,076
2022		2,213
2023		2,255
2024		2,297
Thereafter		14,510
Total future minimum lease payments		25,391
Less imputed interest		(9,787	)
Total lease liabilities	$	15,604

Licensing Service and Supply Agreements [Table Text Block]

	Paid from inception/acquisition to December 31, 2019		Future Commitments (1)		Terms
Amgen Fremont, Inc. (formerly Abgenix)	$	1,350	$	5,750	Milestones and royalties to use XenoMouse ® technology for generating fully human antibodies to PSMA LLC’s PSMA antigen.
Former member of PSMA LLC	$	504	$	52,188	Annual minimum royalty payments and milestones to use technology related to PSMA.
Selexis Commercial License Agreement	$	124	$	1,824	Milestones and royalties to use Selexis technology related to PSMA Antibodies.
University of Zurich and the Paul Scherrer Institute	$	590	$	925	Annual maintenance and license fee payments, milestones and royalties in respect of licensed technology related to 1404.
University of Western Ontario 2003 Agreement	$	41	$	151	Annual minimum royalty, administration and milestone payments in respect of licensed technology related to AZEDRA.
Johns Hopkins University Technology	$	435	$	2,500	Annual minimum royalty payments and milestones to use technology related to PyL.